Tatva Chintan Pharma Chem Limited — PPTs, 28-01-2025: Investor Presentation

**Financial Highlights:** For Q3FY25, Tatva Chintan reported revenue from operations of ₹859 million, showing a 2% year-on-year increase. However, the EBITDA excluding other income dropped 36% to ₹71 million, indicating a significant contraction in margins to 8.2% from 13.1% in the corresponding quarter last year. In the nine months ended FY25, total revenue reached ₹2,749 million, a 7% decline year-on-year, while EBITDA decreased by 51% to ₹256 million, resulting in a margin of 9.3%.

**Strategic Initiatives and Growth Drivers:** The company has successfully initiated operations at its new distillation plant, enhancing production capacity for key products. They are focusing on R&D for high-purity products tailored for the semiconductor and electronics sectors, which are anticipated to drive future growth.

**Business Developments:** Tatva maintains a strong international presence, exporting to over 25 countries, with subsidiaries in the USA and Netherlands facilitating overseas operations.

**Market Position and Competitive Advantage:** The company operates in niche specialty chemicals with minimal competition, emphasizing sustainable production methods. This positions them favorably amid evolving industry dynamics.

**Investor Implications:** Despite recent challenges reflected in financial performance, there are signs of stabilization in raw material prices and market demand, suggesting a positive outlook for recovery. Investors should monitor the company's ongoing strategic initiatives and market conditions for potential growth opportunities.